The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TBC AstraZeneca Pty Ltd
Product name
TBC
Sponsor
Accepted date
Jan-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
For the treatment of locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Application type
C (new indication)
Publication date
Jan-2024
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.